Literature DB >> 11904117

Hypothyroidism in patients with multiple myeloma following treatment with thalidomide.

Ashraf Z Badros1, Eric Siegel, Donald Bodenner, Maurizio Zangari, Jerome Zeldis, Bart Barlogie, Guido Tricot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11904117     DOI： 10.1016/s0002-9343(01)01137-8

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  16 in total

Review 1.  Anticancer Drug-induced Thyroid Dysfunction.

Authors:  Saptarshi Bhattacharya; Alpesh Goyal; Parjeet Kaur; Randeep Singh; Sanjay Kalra
Journal:  Eur Endocrinol       Date:  2020-02-04

Review 2.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

Review 3.  Thyroid dysfunction from antineoplastic agents.

Authors:  Ole-Petter Riksfjord Hamnvik; P Reed Larsen; Ellen Marqusee
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506

Review 4.  2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy.

Authors:  Ilaria Muller; Carla Moran; Beatriz Lecumberri; Brigitte Decallonne; Neil Robertson; Joanne Jones; Colin M Dayan
Journal:  Eur Thyroid J       Date:  2019-07-04

5.  Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma.

Authors:  D M Greenfield; E Boland; Y Ezaydi; R J M Ross; S H Ahmedzai; J A Snowden
Journal:  Bone Marrow Transplant       Date:  2014-04-07       Impact factor: 5.483

6.  Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism.

Authors:  Wade T Iams; Megan L Hames; Judy P Tsai; Kimberly B Dahlman; Mahsa S Talbott; Kristy L Richards; Nishitha M Reddy
Journal:  Exp Hematol       Date:  2014-10-28       Impact factor: 3.084

Review 7.  Endocrine side effects of broad-acting kinase inhibitors.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

Review 8.  Management of thalidomide toxicity.

Authors:  Irene M Ghobrial; S Vincent Rajkumar
Journal:  J Support Oncol       Date:  2003 Sep-Oct

Review 9.  Endocrine dysfunction in leprosy.

Authors:  A M O Leal; N T Foss
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-16       Impact factor: 3.267

10.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Authors:  Waqas Rehman; Lisa M Arfons; Hillard M Lazarus
Journal:  Ther Adv Hematol       Date:  2011-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.